Staquis

RSS

Withdrawn

This medicine's authorisation has been withdrawn

crisaborole
MedicineHumanWithdrawn

Maltese is available via eTranslation, the European Commission's machine translation service.

Translate to Maltese | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 31 January 2022, the European Commission withdrew the marketing authorisation for Staquis (crisaborole) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Pfizer Europe MA EEIG, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Staquis was granted marketing authorisation in the EU on 27 March 2020 for the treatment of mild to moderate atopic dermatitis. The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU. 

The European Public Assessment Report (EPAR) for Staquis is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (328.69 KB - PDF)

Ara

español (ES) (281.81 KB - PDF)

Ara

čeština (CS) (320.82 KB - PDF)

Ara

dansk (DA) (281.27 KB - PDF)

Ara

Deutsch (DE) (285.3 KB - PDF)

Ara

eesti (ET) (270.41 KB - PDF)

Ara

ελληνικά (EL) (329.52 KB - PDF)

Ara

français (FR) (283.57 KB - PDF)

Ara

hrvatski (HR) (303.39 KB - PDF)

Ara

italiano (IT) (280.3 KB - PDF)

Ara

latviešu (LV) (329.73 KB - PDF)

Ara

lietuvių (LT) (305.64 KB - PDF)

Ara

magyar (HU) (318.99 KB - PDF)

Ara

Malti (MT) (320.18 KB - PDF)

Ara

Nederlands (NL) (282.3 KB - PDF)

Ara

polski (PL) (321.05 KB - PDF)

Ara

português (PT) (283.06 KB - PDF)

Ara

română (RO) (303.92 KB - PDF)

Ara

slovenčina (SK) (319.54 KB - PDF)

Ara

slovenščina (SL) (317.49 KB - PDF)

Ara

suomi (FI) (279.2 KB - PDF)

Ara

svenska (SV) (281.27 KB - PDF)

Ara

Product information

български (BG) (1.77 MB - PDF)

Ara

español (ES) (652.9 KB - PDF)

Ara

čeština (CS) (854.6 KB - PDF)

Ara

dansk (DA) (701.91 KB - PDF)

Ara

Deutsch (DE) (631.59 KB - PDF)

Ara

eesti (ET) (632.47 KB - PDF)

Ara

ελληνικά (EL) (1.11 MB - PDF)

Ara

français (FR) (646.88 KB - PDF)

Ara

hrvatski (HR) (686.34 KB - PDF)

Ara

italiano (IT) (654.17 KB - PDF)

Ara

latviešu (LV) (954.3 KB - PDF)

Ara

lietuvių (LT) (666.03 KB - PDF)

Ara

magyar (HU) (907.86 KB - PDF)

Ara

Malti (MT) (990.45 KB - PDF)

Ara

Nederlands (NL) (743.33 KB - PDF)

Ara

polski (PL) (844.03 KB - PDF)

Ara

português (PT) (718.77 KB - PDF)

Ara

română (RO) (764.23 KB - PDF)

Ara

slovenčina (SK) (932.49 KB - PDF)

Ara

slovenščina (SL) (945.75 KB - PDF)

Ara

suomi (FI) (699.75 KB - PDF)

Ara

svenska (SV) (617.55 KB - PDF)

Ara

Íslenska (IS) (603.78 KB - PDF)

Ara

norsk (NO) (599.01 KB - PDF)

Ara
Latest procedure affecting product information:N/0006
01/10/2021
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (201.75 KB - PDF)

Ara

español (ES) (186.74 KB - PDF)

Ara

čeština (CS) (195.66 KB - PDF)

Ara

dansk (DA) (187.51 KB - PDF)

Ara

Deutsch (DE) (188.07 KB - PDF)

Ara

eesti (ET) (186.99 KB - PDF)

Ara

ελληνικά (EL) (201.24 KB - PDF)

Ara

français (FR) (187.58 KB - PDF)

Ara

hrvatski (HR) (186.48 KB - PDF)

Ara

italiano (IT) (186.31 KB - PDF)

Ara

latviešu (LV) (195.58 KB - PDF)

Ara

lietuvių (LT) (187.21 KB - PDF)

Ara

magyar (HU) (195.07 KB - PDF)

Ara

Malti (MT) (199.97 KB - PDF)

Ara

Nederlands (NL) (186.56 KB - PDF)

Ara

polski (PL) (195.15 KB - PDF)

Ara

português (PT) (186.88 KB - PDF)

Ara

română (RO) (186.68 KB - PDF)

Ara

slovenčina (SK) (195.31 KB - PDF)

Ara

slovenščina (SL) (193.6 KB - PDF)

Ara

suomi (FI) (186.56 KB - PDF)

Ara

svenska (SV) (186.08 KB - PDF)

Ara

Íslenska (IS) (187.47 KB - PDF)

Ara

norsk (NO) (191.95 KB - PDF)

Ara

Product details

Name of medicine
Staquis
Active substance
Crisaborole
International non-proprietary name (INN) or common name
crisaborole
Therapeutic area (MeSH)
Dermatitis, Atopic
Anatomical therapeutic chemical (ATC) code
D11AH06

Pharmacotherapeutic group

Other dermatological preparations

Therapeutic indication

Staquis is indicated for treatment of mild to moderate atopic dermatitis in adults and paediatric patients from 2 years of age with ? 40% body surface area (BSA) affected.

Authorisation details

EMA product number
EMEA/H/C/004863
Marketing authorisation holder
Pfizer Europe MA EEIG

Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Opinion adopted
30/01/2020
Marketing authorisation issued
27/03/2020
Revision
6

Assessment history

This page was last updated on

Share this page